Strike three for Rova-T has AbbVie cutting its losses - PMLiVE

Strike three for Rova-T has AbbVie cutting its losses  PMLiVE

AbbVie has run out of patience on its antibody-drug conjugate Rova-T after yet another failed trial in lung cancer, and has decided to abandon the programme.